Astrana Health, Inc. (ASTH)
(Real Time Quote from BATS)
$49.50 USD
+0.17 (0.35%)
Updated Jul 22, 2024 02:58 PM ET
4-Sell of 5 4
C Value F Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASTH 49.50 +0.17(0.35%)
Will ASTH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ASTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASTH
Here is Why Growth Investors Should Buy Astrana Health, Inc. (ASTH) Now
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
ASTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Option Care (OPCH) Q1 Earnings and Revenues Surpass Estimates
Astrana Health Inc. (ASTH) Q4 Earnings and Revenues Top Estimates
Other News for ASTH
Astrana Health and Elation Health Form Nationwide Partnership to Expand Sustainable Support Infrastructure for Primary Care Physicians
Astrana Health and Elation Health announce partnership
Astrana Health and Elation Health partner in infrastructure solution
Astrana Health and Anthem Blue Cross Establish Partnership to Deliver High-Quality Coordinated Care
Astrana Health price target raised to $48 from $45 at Stifel